The role of COX expression in the prognostication of overall survival of canine and feline cancer: A systematic review
Open Access
- 10 March 2021
- journal article
- review article
- Published by Wiley in Veterinary Medicine and Science
- Vol. 7 (4) , 1107-1119
Abstract
Cyclooxygenase (COX) isoforms‐1 and ‐2 have been extensively investigated in cancer. Although COX‐2 is the isoform most studied and has been described in several malignancies associated with histologic criteria of malignancy and worse prognosis, COX‐1 has also been linked to some forms of cancer. With the present review our aim was to summarize the current state of knowledge and clarify if and in which type of tumours COX‐1 and/or COX‐2 expression have real prognostic implications. We searched PubMed database for prognostic studies using predefined inclusion criteria in order to ascertain the prognostic value of COX‐1 and COX‐2 in malignant neoplasia in dogs and cats. Eighteen studies were analysed. COX‐2 was shown to be a negative prognostic factor in canine and feline mammary tumours, canine mast cell tumour, canine melanoma, canine osteosarcoma and canine renal cell carcinoma. COX‐1 showed a negative prognostic value in feline oral squamous cell carcinoma (SCC). We found high heterogeneity among studies regarding COX immunohistochemical evaluation methodology even in the same type of neoplasia pointing out the need for its standardization at least by tumour type. The available data support the use of COX‐2 as a prognostic factor in canine (mammary carcinoma, mast cell tumour, melanoma, osteosarcoma and renal carcinoma) and feline (mammary carcinoma) cancers. For COX‐1, its use is advised in feline oral SCC.Keywords
This publication has 74 references indexed in Scilit:
- Expression of Ki67, BCL-2, and COX-2 in Canine Cutaneous Mast Cell TumorsVeterinary Pathology, 2012
- Cancer biomarkersMolecular Oncology, 2012
- The role of Cox-2 expression in the prognosis of dogs with malignant mammary tumoursResearch in Veterinary Science, 2010
- Cancer and Inflammation: Promise for Biologic TherapyJournal of Immunotherapy, 2010
- Eicosanoids and cancerNature Reviews Cancer, 2010
- The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and ElaborationPLOS Medicine, 2009
- COX-2 expression in canine and feline invasive mammary carcinomas: correlation with clinicopathological features and prognostic fmolecular markersBreast Cancer Research and Treatment, 2006
- Cyclooxygenase-2 Expression in Canine Appendicular OsteosarcomasJournal of Veterinary Internal Medicine, 2004
- Cyclooxygenase-2 Expression in Canine Appendicular OsteosarcomasJournal of Veterinary Internal Medicine, 2004
- Piroxicam Therapy in 34 Dogs With Transitional Cell Carcinoma of the Urinary BladderJournal of Veterinary Internal Medicine, 1994